Literature DB >> 28417540

Medium-chain triglycerides given in the early stage of mild-to-moderate Alzheimer's disease enhance memory function.

Ayako Kimoto1, Tohru Ohnuma1, Aiko Toda1, Yuto Takebayashi1, Ryoko Higashiyama1, Yuko Tagata1, Masanobu Ito1, Tsuneyoshi Ota1, Nobuto Shibata1, Heii Arai1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28417540     DOI： 10.1111/psyg.12257

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN： 1346-3500            Impact factor:   2.440


× No keyword cloud information.
  4 in total

1.  Impact of medium-chain triglycerides on gait performance and brain metabolic network in healthy older adults: a double-blind, randomized controlled study.

Authors:  Tatsushi Mutoh; Keiko Kunitoki; Yasuko Tatewaki; Shuzo Yamamoto; Benjamin Thyreau; Izumi Matsudaira; Ryuta Kawashima; Yasuyuki Taki
Journal:  Geroscience       Date:  2022-04-05       Impact factor: 7.581

Review 2.  Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.

Authors:  Fei Yin
Journal:  FEBS J       Date:  2022-01-07       Impact factor: 5.622

Review 3.  Ketone Supplementation: Meeting the Needs of the Brain in an Energy Crisis.

Authors:  Angela M Poff; Sara Moss; Maricel Soliven; Dominic P D'Agostino
Journal:  Front Nutr       Date:  2021-12-23

Review 4.  Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential.

Authors:  Yashi Mi; Guoyuan Qi; Roberta Diaz Brinton; Fei Yin
Journal:  Antioxid Redox Signal       Date:  2020-04-21       Impact factor: 8.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.